Genelux (NASDAQ:GNLX) SVP Sells $10,815.84 in Stock

by · The Markets Daily

Genelux Corporation (NASDAQ:GNLX – Get Free Report) SVP Yong Yu sold 3,219 shares of the company’s stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $3.36, for a total transaction of $10,815.84. Following the completion of the transaction, the senior vice president owned 146,817 shares in the company, valued at approximately $493,305.12. This trade represents a 2.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Yong Yu also recently made the following trade(s):

  • On Monday, November 17th, Yong Yu sold 973 shares of Genelux stock. The shares were sold at an average price of $5.37, for a total transaction of $5,225.01.

Genelux Price Performance

GNLX stock traded down $0.11 during midday trading on Thursday, reaching $4.40. The company had a trading volume of 77,387 shares, compared to its average volume of 191,698. Genelux Corporation has a 1 year low of $1.99 and a 1 year high of $8.53. The company has a market capitalization of $167.42 million, a P/E ratio of -5.00 and a beta of 0.06. The firm has a 50-day moving average price of $5.74 and a 200-day moving average price of $4.17.

Genelux (NASDAQ:GNLX – Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.02. On average, equities analysts predict that Genelux Corporation will post -0.88 EPS for the current year.

Hedge Funds Weigh In On Genelux

Hedge funds have recently modified their holdings of the company. Susquehanna International Group LLP raised its stake in shares of Genelux by 140.3% during the third quarter. Susquehanna International Group LLP now owns 52,383 shares of the company’s stock valued at $220,000 after acquiring an additional 30,583 shares during the last quarter. Qube Research & Technologies Ltd grew its stake in shares of Genelux by 101.3% in the third quarter. Qube Research & Technologies Ltd now owns 37,224 shares of the company’s stock worth $156,000 after purchasing an additional 18,734 shares during the last quarter. Creative Planning increased its holdings in Genelux by 4.7% during the 3rd quarter. Creative Planning now owns 46,108 shares of the company’s stock valued at $194,000 after purchasing an additional 2,084 shares during the period. Woodward Diversified Capital LLC raised its position in Genelux by 3.7% during the 3rd quarter. Woodward Diversified Capital LLC now owns 1,844,099 shares of the company’s stock valued at $7,745,000 after purchasing an additional 65,813 shares during the last quarter. Finally, 5T Wealth LLC lifted its holdings in Genelux by 33.9% in the 3rd quarter. 5T Wealth LLC now owns 24,101 shares of the company’s stock worth $101,000 after buying an additional 6,100 shares during the period. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on GNLX. Weiss Ratings restated a “sell (e+)” rating on shares of Genelux in a research report on Wednesday, October 8th. Maxim Group set a $20.00 price objective on Genelux in a report on Tuesday, October 21st. Loop Capital set a $16.00 target price on Genelux in a research report on Tuesday, October 21st. Finally, Lake Street Capital assumed coverage on Genelux in a research note on Tuesday, October 21st. They issued a “buy” rating and a $16.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $21.00.

View Our Latest Analysis on Genelux

Genelux Company Profile

(Get Free Report)

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.

Further Reading